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Context: Dipeptidyl peptidase 4 (DPP4) inhibitors may increase the risk of heart failure. Decreased
degradation of vasoactive peptides like substance P [also degraded by angiotensin-converting enzyme
(ACE)] and Y1 agonists peptide YY (PYY 1-36) and neuropeptide Y (NPY 1-36) could contribute.
Objective: This study tested the hypothesis that there is an interactive effect of DPP4 inhibition and
ACE inhibition (vs antihypertensive control subjects) on vasoactive peptides after a mixed meal.
Participants and Design: Fifty-three patients with type 2 diabetes and hypertension were ran-
domized to double-blind treatment with ramipril, valsartan, or amlodipine for 15 weeks in parallel
groups. During the 5th, 10th, and 15th weeks, participants also received placebo 1 placebo, sitagliptin
100 mg/d 1 placebo, and sitagliptin 1 aprepitant 80 mg/d in random order. On the last day of each
crossover treatment, participants underwent a mixed-meal study.
Results: Sitagliptin increased postprandial glucagon-like peptide-1 and decreased glucose in all
antihypertensive groups. Sitagliptin increased NPY 1-36 and decreased Y2 agonists NPY 3-36 and PYY
3-36 in all groups. During ramipril or valsartan, but not amlodipine, sitagliptin increased postprandial
norepinephrine; substance P receptor blockade with aprepitant prevented this effect. Despite increased
norepinephrine, sitagliptin decreased postprandial blood pressure during ACE inhibition.
Conclusion: DPP4 inhibition increases postprandial concentrations of the Y1 agonist NPY 1-36.
During treatment with an ACE inhibitor or angiotensin receptor blocker, DPP4 inhibition increased
postprandial norepinephrine through a substance P receptor–dependent mechanism. Increased NPY 1-
36 and norepinephrine could increase risk of heart failure but did not result in higher postprandial
blood pressure.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; DBP,
diastolic blood pressure; DPP4, dipeptidyl peptidase 4; GLP-1, glucagon like peptide-1; MAP, mean arterial pressure; NK1, neu-
rokinin receptor type 1; NPY, neuropeptide Y; PYY, peptide YY; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood
pressure; T2DM, type 2 diabetes mellitus; VAS, visual analog scale.
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Dipeptidyl peptidase-4 (DPP4) inhibitors are widely used in the treatment of patients with
type 2 diabetes mellitus (T2DM). DPP4 is a transmembrane serine protease that selectively
cleaves the amino terminal dipeptide from peptides with a penultimate proline or alanine,
including the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic peptide [1]. DPP4 inhibitors improve glucose homeostasis by preventing deg-
radation of incretins secreted after ingestion of a meal [2]. GLP-1 receptor activation increases
postprandial insulin secretion, decreases glucagon release, and delays gastric emptying [2].
GLP-1 agonists generally have favorable cardiovascular outcomes in patients with T2DM
and may reduce cardiovascular risk [3]. Even though DPP4 inhibitors increase endogenous
GLP-1, they do not reduce cardiovascular disease and in some studies promote heart failure
[4–6]. In addition to preventing the degradation of GLP-1, DPP4 inhibitors prevent the
degradation of other vasoactive peptides, such as substance P, peptide YY (PYY 1-36), and
neuropeptide Y (NPY 1-36) [1, 7]. Substance P is released from sensory C fibers and activates
sympathetic nerve terminals via the neurokinin receptor type 1 (NK1) receptor, leading to
release of norepinephrine and NPY 1-36 [8, 9]. PYY 1-36 is released by L cells of the intestine
into plasma in response to a meal [10]. NPY 1-36 and PYY 1-36 activate the Y1 receptor,
whereas their metabolites, via DPP4, NPY 3-36, and PYY 3-36, do not have activity at Y1 and
activate Y2 and Y5 receptors [10–12]. Y1 receptor activation leads to vasoconstriction, po-
tentiation of norepinephrine and alpha-adrenergic responses [13], and activation of cardiac
fibroblasts [14]. In contrast, Y2 activation decreases sympathetic nerve terminal activation
and norepinephrine release [11, 12] and suppresses appetite in animal models [10].
Over two-thirds of patients with T2DM also have hypertension, but the interactive effects
of DPP4 inhibitors and antihypertensive medications on vasoactive peptides have not been
extensively studied. Substance P is a shared substrate of DPP4 and angiotensin-converting
enzyme (ACE). Combined ACE and DPP4 inhibition increases norepinephrine concentra-
tions at baseline and in response to intra-arterial substance P infusion [15, 16]. In addition,
DPP4 inhibition potentiates Y1 receptor–dependent vasoconstriction in response to intra-
arterial NPY 1-36 infusion during interruption of the renin-angiotensin-aldosterone system
(RAAS) by either ACE inhibition or angiotensin receptor blockade [17]. Increased substance
P, NPY, and norepinephrine concentrations could contribute to an increased risk of heart
failure [18, 19].
This study examined concentrations of Y1 agonists PYY 1-36 and NPY 1-36 and substance
P receptor–dependent effects of DPP4 inhibition during concurrent antihypertensive ther-
apy. Specifically, we compared the effect of crossover therapy with placebo, the DPP4 in-
hibitor sitagliptin, and sitagliptin given in combination with the substance P (NK1) receptor
blocker aprepitant on hormone and hemodynamic responses to a mixed meal in patients with
T2DM and hypertension who were first randomized to treatment with one of three anti-
hypertensive agents: an ACE inhibitor, an angiotensin receptor blocker (ARB), or a calcium
channel blocker.We hypothesized (i) that combinedDPP4 and ACE inhibition would increase
norepinephrine and NPY 1-36 in response to a mixedmeal through a substance P–dependent
mechanism (aim 1) and (ii) that DPP4 inhibition could potentiate the Y1-dependent effects of
PYY 1-36 and NPY 1-36 after a mixed meal by decreasing their degradation through a
substance P–independent mechanism (aim 2). We included ARB-treated patients to evaluate
the possibility that DPP4 inhibition interacts with drugs that interrupt the RAAS, in-
dependent of ACE activity. We included patients treated with a calcium channel blocker to
exclude the possibility of an interaction between DPP4 inhibition and antihypertensive
therapy independent of the RAAS.
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1. Research Design and Methods
A. Subjects
The study was approved by the Vanderbilt Institutional Review Board and was conducted
according to the Declaration of Helsinki. All volunteers provided written informed consent.
Men and women 18 to 80 years old with T2DM and hypertension were eligible for enrollment.
T2DM was defined by an untreated HbA1c $6.5% (48 mmol/mol) or greater, fasting plasma
glucose $126 mg/dL (7.0 mmol/L), or 2-hour plasma glucose $200 mg/dL (11.1 mmol/L)
following a 75-g oral glucose load or treatment with antidiabetic medication for at least
6 months. Hypertension was defined as a seated systolic blood pressure (SBP) $130 mm Hg
or diastolic blood pressure (DBP) $80 mm Hg on at least three occasions or treatment with
antihypertensive medications for at least 6 months, consistent with consensus statements on
blood pressure control in individuals with diabetes at risk for cardiovascular disease [20].
Pregnancy was excluded in women of childbearing potential by b-human chorionic gonad-
otropin testing. Participants with poorly controlled diabetes [HbA1c .8.7% (72 mmol/mol)],
long-term (.12 months) use of an antidiabetic medication other than metformin, use of
insulin, type 1 diabetes, or secondary hypertension were excluded.
B. Protocol
Participants taking antihypertensive and/or antidiabetic medications other than thiazide
diuretics or metformin underwent washout from these other medicines for a minimum of
3 weeks (4 weeks for spironolactone). After washout, participants were randomized in a 1:1:1
ratio to ramipril, valsartan, or amlodipine at the following doses for 15weeks: ramipril 5mg/d
for 3 days, then 10 mg/d; valsartan 160 mg/d for 3 days, then 320 mg/d; or amlodipine 5 mg/d
for 3 days, then 10 mg/d (Fig. 1). After the first 4 weeks of antihypertensive treatment,
subjects were randomized to the first of three 1-week crossover therapies: placebo/d 1
placebo/d, sitagliptin 100 mg/d 1 placebo/d, and sitagliptin 100 mg/d 1 aprepitant (125 mg,
then 80 mg/d). Each crossover treatment was separated by 4 weeks to provide sufficient
washout to avoid carryover effects (Fig. 1).
During the last day of each 1-week crossover treatment, subjects presented to the Van-
derbilt Clinical Research Center after an overnight fast for a study day. Subjects were given
their antihypertensive medication and their last dose of crossover medications between 7:00
and 8:00 AM. Blood pressure and heart rate were measured via an automated oscillometric
device every 5 minutes during each study day (Dinamap; Critikon, Carlsbad, CA). Five hours
after the last dose of study medication, subjects ingested a standardized mixed meal of 712
calories (45% fat, 33% carbohydrate, 22% protein) over 15 minutes. Blood samples were
collected through an indwelling catheter before the meal and for 4 hours after the meal at
time points 0, 15, 30, 45, 60, 90, 120, 150, 180, and 240 minutes. Before the meal and 60 and
240 minutes after, subjects completed a visual analog scale (VAS) to assess level of satiety
and desire for a specific food type, as previously validated by Flint et al. [21].
C. Laboratory Analyses
Plasma glucose was measured via glucose oxidase method using a glucose analyzer (YSI Life
Sciences, Yellow Springs, OH) immediately after collection. All remaining samples were
stored at280°C in aliquots until the time of assay. Plasma insulin samples were collected in
tubes containing aprotinin, and insulin was measured by radioimmunoassay (EMD Milli-
pore, Billerica, MA) [22]. The assay cross-reacts with 38% intact proinsulin but not with
C-peptide (#0.01%). Samples for GLP-1, PYY, and NPY were collected in tubes containing a
cocktail of protease inhibitors to avoid ex vivo degradation of peptides (apstatin, vildagliptin,
phenylmethylsulfonyl fluoride, EDTA, and phosphoramidon). Active GLP-1 was measured
via Milliplex Human Metabolic Hormone Magnetic Bead Panel (EMD Millipore, Billerica,
MA) and multiplex immunoassay (Meso Scale Discovery, Gaithersburg, MD). Total PYY was
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measured via radioimmunoassay, with 100% specificity to human PYY 1-36 and PYY 3-36,
with sensitivity to 10 pg/mL (EMDMillipore, St. Charles, MO) [23]. PYY 3-36 was measured
via radioimmunoassay, with 100% specificity for the 3-36 metabolite, no cross reactivity with
PYY 1-36, and sensitivity to 20 pg/mL (EMD Millipore) [24]. PYY 1-36 was estimated as the
difference between total PYY and PYY 3-36. NPY and its metabolites were measured via
liquid chromatography–mass spectrometry with ultra–high-pressure liquid chromatography.
Plasma norepinephrine was measured via HPLC using electrochemical detection. Serum
lipids were measured via colorimetric enzymatic assay (with reagents from Thermo-Fisher
Infinity, Middletown, VA). Free fatty acids were measured via gas chromatography.
DPP4 activity was measured by incubating 20 mL serum sample in 80 mL assay buffer
(0.1 M Tris at pH 8.0; Bachem, Torrance, CA) for 30 minutes at 37°C with colorimetric
substrate (2 mM l-glycyl-l-prolyl p-nitroanilide hydrochloride; Sigma-Aldrich, St. Louis, MO)
for a total volume of 200 mL. DPP4 activity was assessed by measuring the increased specific
absorbance at 405 nm at 0, 15, 30 minutes and was expressed as nmol/mL/min.
D. Statistical Analyses
The primary endpoints were norepinephrine and NPY (aim 1) and PYY (aim 2) levels.
Secondary endpoints were blood pressure and heart rate. A sample size of 16 subjects per
antihypertensive group was determined to provide 80% power to detect a difference in
Figure 1. Study protocol. After washout, subjects were randomized in a parallel design to
receive 15 wk of antihypertensive treatment with one of three agents: ramipril, valsartan, or
amlodipine. After 4 wk of treatment, subjects received the first of three 1-wk crossover
interventions: placebo/d 1 placebo/d, sitagliptin 100 mg/d 1 placebo/d, and sitagliptin 100
mg/d 1 aprepitant 125 mg then 80 mg/d, in blinded, random order. Subjects underwent a
mixed meal study day on the seventh and final day of crossover intervention. The three
crossover interventions were separated by 4 wk to avoid carryover effects.
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postprandial norepinephrine concentrations between crossover treatments comparable to
that observed in a prior study of a DPP4 inhibitor (280 6 89 vs 227 6 49 pg/mL) [25]. This
sample size provided .99% power to detect a difference in PYY 3-36 concentrations com-
parable to that previously reported duringDPP4 inhibition [26]. The effect of DPP4 inhibition
on postprandial endogenous NPY 1-36 concentrations has not been reported previously.
Results are presented as mean 6 SD unless otherwise noted. Although we have designed
the study to avoid a carryover effect, we used a mixed-effects model for baseline measure-
ments to test for potential first-order carryover effects. We found no evidence of carryover for
any treatment on norepinephrine, NPY 1-36, NPY 3-36, PYY 1-36, GLP-1, insulin, SBP, DBP,
mean arterial pressure (MAP), heart rate, triglycerides, or very-low-density lipoprotein. In
the ramipril group only, there was evidence for carryover effect of sitagliptin1 aprepitant on
glucose. In the valsartan group only, there was evidence for a carryover effect of sitagliptin
and sitagliptin 1 aprepitant on PYY 3-36 concentrations.
We used repeated measures ANOVA to evaluate the effect of crossover treatment (pla-
cebo1 placebo, sitagliptin1 placebo, sitagliptin1 aprepitant) within each antihypertensive
treatment group, followed by paired t tests between crossover treatments. For glucose in the
ramipril group and PYY 3-36 in the valsartan group, we also fitted a mixed-effects model on
crossover treatments with a carryover term included as a covariate. For blood pressure and
heart rate, we conducted additional multivariable analysis using generalized least squares
linear models with compound symmetry error covariance to control for sex and race. All
hypotheses were tested at the level of a 5 0.05. We performed analyses using SPSS for
Windows (Version 24.0, SPSS, Chicago) and the open source statistical package R (version
3.5.1, R Development Core Team, 2018).
2. Results
A. Participant Characteristics
Fifty-three participants were randomized to antihypertensive therapy and received at least
one of the randomized crossover treatments (Fig. 1, Supplemental Fig. 1 [27]). One par-
ticipant in the ramipril treatment arm and one in the valsartan arm dropped out after the
first crossover treatment, and these participants were not included in the analyses. Table 1
shows the characteristics of participants within each antihypertensive armwho completed all
three crossover treatments.
B. Effect of DPP4 Inhibition on Baseline (Preprandial) Characteristics
Table 2 provides the effect of crossover treatment on baseline characteristics (prior to mixed
meal ingestion) within each antihypertensive treatment group. Sitagliptin increased fasting
GLP-1 concentrations in all three antihypertensive groups. Sitagliptin did not affect fasting
insulin concentrations. Sitagliptin significantly decreased fasting glucose in the valsartan
and amlodipine groups. In the valsartan group, fasting glucose was significantly reduced only
during sitagliptin and aprepitant, and fasting glucose was significantly lower during sita-
gliptin 1 aprepitant than during sitagliptin 1 placebo.
Treatment with sitagliptin with or without aprepitant significantly decreased fasting PYY
3-36 concentrations in all three antihypertensive treatment groups (Table 2). Sitagliptin
increased fasting PYY 1-36 only in the valsartan group. Sitagliptin decreased fasting NPY 3-
36 and increased fasting NPY 1-36 in all three antihypertensive treatment groups. Apre-
pitant did not affect NPY 1-36 or NPY 3-36.
Baseline norepinephrine concentrations were significantly higher during sitagliptin 1
placebo compared with placebo 1 placebo but not during sitagliptin 1 aprepitant in the
ramipril treatment group. There was also a trend toward increased baseline norepinephrine
during sitagliptin 1 placebo in the valsartan treatment group, but this did not reach sta-
tistical significance. There was no effect of crossover therapy on baseline MAP, SBP (not
shown), DBP (not shown), or heart rate in any of the antihypertensive treatment groups.
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C. Effect of DPP4 Inhibition on Metabolic and Hormone Responses to a Mixed Meal
GLP-1 concentrations increased significantly after the mixed meal in all three antihyper-
tensive treatment groups (Fig. 2). Sitagliptin significantly increased GLP-1 concentrations
further after themixedmeal in all treatment groups. Coadministration of the NK1/substance
P receptor antagonist aprepitant blunted the GLP-1 response 60 minutes after the meal in
the ramipril group. There was a significant but small effect of sitagliptin on postprandial
insulin concentration in the ramipril and valsartan treatment groups. In the ramipril
treatment group, aprepitant abolished this effect. Sitagliptin decreased glucose concentra-
tions after the mixed meal in all three antihypertensive treatment groups. Coadministration
of aprepitant slightly but significantly enhanced this effect at baseline in the valsartan
treatment group and 3 to 4 hours after meal ingestion in the amlodipine group.
PYY 1-36 and PYY 3-36 increased after meal ingestion during placebo1 placebo treatment
in all three antihypertensive treatment groups (Fig. 3). There was no effect of sitagliptin
or aprepitant on postprandial PYY 1-36 concentrations. Sitagliptin markedly decreased
postprandial PYY 3-36 concentrations, and there was no effect of NK1/substance P
receptor blockade.
Because we did not detect an effect of meal ingestion on concentrations of NPY 1-36 or its
metabolites in a pilot study of nine participants (data not shown), we analyzed samples for
NPY 1-36 and 3-36 at only two time points (i.e., at baseline and 1 hour after meal ingestion).
NPY 1-36was significantly increased andNPY3-36 significantly decreased during sitagliptin
treatment, and concurrent treatment with aprepitant did not significantly affect this (Fig. 3).
Norepinephrine increased significantly 30 minutes after ingestion of the mixed meal
during placebo treatment. Sitagliptin significantly accentuated the increase in norepi-
nephrine in the ramipril and valsartan treatment groups, although the time-course of
significance was slightly different (Fig. 4). Because norepinephrine concentrations were
statistically similar in the patients treated with ramipril and valsartan during all crossover
treatments, we also analyzed the effect of sitagliptin in the two RAAS inhibitor treat-
ment groups combined. Sitagliptin significantly increased postprandial norepinephrine
Table 1. Baseline Subject Characteristics Before Randomization
Parameter Ramipril (n 5 15) Valsartan (n 5 16) Amlodipine (n5 20) All (n 5 51)
Age, y 52.7 6 5.9 56.5 6 8.8 58.5 6 13.1 56.2 6 10.2
Sex, n (%)
Male 9 (60.0) 10 (62.5) 11 (55.0) 30 (58.8)





12 (80.0) 11 (68.8) 10 (50.0) 33 (64.7)
Black 2 (13.3) 5 (31.3) 7 (35.0) 14 (27.5)
Hispanic white 0 (0) 0 (0) 2 (10.0) 2 (3.9)
Asian 1 (6.7) 0 (0) 1 (5.0) 2 (3.9)
Weight, kg 106.1 6 20.0 96.9 6 19.0 97.4 6 16.6 99.8 6 18.5
BMI, kg/m2 34.6 6 5.3 32.5 6 6.6 33.6 6 5.8 33.5 6 5.9
SBP, mm Hg 131.5 6 11.4 135.0 6 10.3 135.5 6 11.4 134.2 6 11.0
DBP, mm Hg 76.9 6 5.9 82.5 6 7.7 78.3 6 7.7 79.2 6 7.4
Heart rate, bpm 74.8 6 10.6 71.0 6 9.8 71.1 6 10.4 72.2 6 10.2
Fasting blood
glucose, mg/dL
129.1 6 27.5 119.4 6 20.2 118.7 6 28.8 122.0 6 25.9
HbA1c, % (mmol/mol) 6.8 6 1.0 (51 6 12.6) 6.5 6 0.8 (48 6 14.75) 6.5 6 0.7 (48 6 15.84) 6.6 6 0.8 (49 6 14.75)
Triglycerides 165.1 6 63.7 145.7 6 57.5 111.9 6 47.9 138.1 6 59.3
HDL-cholesterol 43.2 6 9.7 43.6 6 12.3 43.9 6 9.2 43.6 6 10.2
Data are presented as means 6 SD or number and percent.
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein.
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concentrations. Concurrent treatment with the NK1 receptor blocker aprepitant abolished
this effect of sitagliptin on postprandial norepinephrine concentrations.
D. Effect of DPP4 Inhibition on Satiety After Mixed Meal Ingestion
Fullness increased and hunger decreased significantly 1 hour after the meal during all three
crossover treatments in all three antihypertensive treatment groups (data not shown). The
feeling of satisfaction increased significantly 1 hour after the meal in all three antihyper-
tensive treatment groups. In the ramipril treatment group only, the increase in satisfaction
was diminished during sitagliptin 1 placebo (VAS 4.67 6 2.34 at 1 hour) compared with
during placebo 1 placebo (VAS 5.85 6 2.03, P 5 0.008) or sitagliptin 1 aprepitant (VAS
5.85 6 2.42, P 5 0.037). There was no other effect of sitagliptin or NK1 receptor blockade on
fullness, hunger, or the feeling of satisfaction.
E. Effect of DPP4 Inhibition on Blood Pressure and Heart Rate After Mixed Meal Ingestion
Fasting blood pressure and heart rate were similar among treatment days. In the ramipril
treatment group, postprandial MAP was significantly lower during sitagliptin1 placebo and
during sitagliptin 1 aprepitant compared with during placebo 1 placebo (Fig. 5). This
reflected a significant effect of sitagliptin1 placebo on SBP (P5 0.025) and a significant effect
of sitagliptin1 aprepitant on both SBP (P5 0.020) and DBP (P5 0.026). There was no effect
of sitagliptin alone on blood pressure in the valsartan or the amlodipine treatment group.
In the amlodipine treatment group, sitagliptin 1 aprepitant decreased DBP (P 5 0.003
vs placebo 1 placebo and P 5 0.015 vs sitagliptin 1 placebo) and MAP (P 5 0.007 vs
Figure 2. Effect of 1-wk treatment with placebo 1 placebo (white circle), sitagliptin 100 mg/
d 1 placebo (blue circle), and sitagliptin 100 mg/d 1 aprepitant 125 mg followed by 80 mg/d
(red circle) on GLP-1, insulin, and glucose concentrations after ingestion of a mixed meal
(time 0) in patients with type 2 diabetes and hypertension receiving ramipril 10 mg/d (n 5
15), valsartan 360 mg/d (n 5 16), or amlodipine 10 mg/d (n 5 20). *P , 0.05 vs placebo.
†P , 0.05 vs sitagliptin 1 aprepitant.
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placebo 1 placebo and P 5 0.054 vs sitagliptin 1 placebo), suggesting an effect of aprepitant
unrelated to DPP4 inhibition. There was no significant effect of sitagliptin1 placebo on heart
rate in any treatment group. Sitagliptin 1 aprepitant decreased heart rate vs sitagliptin 1
placebo in the valsartan treatment group and vs placebo 1 placebo in the amlodipine
treatment group, again suggesting an effect unrelated to DPP4 inhibition. Similar results
were observed after adjusting for race and sex.
F. Relationship Among Y1 and Y2 Agonist Concentrations, Norepinephrine, Blood Pressure,
and Heart Rate
At 1 hour after meal ingestion, NPY 1-36 concentrations correlated significantly with
norepinephrine during placebo 1 placebo (r 5 0.370, P 5 0.008), sitagliptin 1 placebo (r 5
0.334, P 5 0.018), and sitagliptin 1 aprepitant (r 5 0.368, P 5 0.010). NPY 1-36 correlated
with PYY 1-36 during placebo 1 placebo (r 5 0.374, P 5 0.007) but not during either
sitagliptin treatment.
3. Discussion
This study examined Y1 agonist concentrations and substance P receptor–dependent effects
of DPP4 inhibition in response to a meal during concurrent antihypertensive therapy. We
report that sitagliptin increased circulating concentrations of the endogenous Y1 agonist
NPY 1-36 and decreased circulating concentrations of the Y2 agonist NPY 3-36. The effects of
DPP4 inhibition on Y1 and Y2 agonists did not involve endogenous substance P and were
Figure 3. Effect of 1-wk treatment with placebo 1 placebo (white), sitagliptin 100 mg/d 1
placebo (blue), and sitagliptin 100 mg/d 1 aprepitant 125 mg followed by 80 mg/d (red) on
PYY 1-36 (square), PYY 3-36 (circle), NPY 1-36 (square), and NPY 3-36 (circle) in patients
with type 2 diabetes and hypertension receiving ramipril 10 mg/d (n 5 15), valsartan
360 mg/d (n 5 16) or amlodipine 10 mg/d (n 5 20). *P , 0.05 vs placebo. †P , 0.05 vs
sitagliptin 1 aprepitant.
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independent of concurrent antihypertensive therapy. In contrast, during treatment with
either an ACE inhibitor or an ARB but not during treatment with a calcium channel
blocker, DPP4 inhibition increased postprandial norepinephrine concentrations through a
Figure 4. Effect of 1-wk treatment with placebo 1 placebo (white circle), sitagliptin 100 mg/d 1
placebo (blue circle), and sitagliptin 100 mg/d 1 aprepitant 125 mg followed by 80 mg/d
(red circle) on plasma norepinephrine concentrations in patients with type 2 diabetes and
hypertension receiving ramipril 10 mg/d (n 5 15), valsartan 360 mg/d (n 5 16), or
amlodipine 10 mg/d (n 5 20) *P , 0.05 vs placebo. †P , 0.05 vs sitagliptin 1 aprepitant.
Figure 5. Effect of 1-wk treatment with placebo 1 placebo (white circle), sitagliptin 100 mg/d
1 placebo (blue circle), and sitagliptin 100 mg/d 1 aprepitant 125 mg followed by 80 mg/d
(red circle) on MAP and heart rate in patients with type 2 diabetes and hypertension receiving
ramipril 10 mg/d (n 5 15), valsartan 360 mg/d (n 5 16), or amlodipine 10 mg/d (n 5 20). The
P values provided are for comparison of the mean postprandial values among treatment arms.
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substance P (NK1) receptor–dependent mechanism. Despite increased concentrations of the
vasoconstrictor Y1 agonist NPY 1-36 and norepinephrine, there was no effect of sitagliptin on
fasting blood pressure, and sitagliptin lowered postprandial blood pressure during ACE
inhibition. Blockade of the substance P (NK1) receptor with aprepitant appeared to lower
postprandial blood pressure and heart rate independently of DPP4 inhibition.
This is study reports the effect of DPP4 inhibition on endogenous NPY 1-36 and NPY 3-36
concentrations after a meal. A few groups have reported the effect of DPP4 inhibition on
responses to exogenous NPY 1-36 in adipocytes, where NPY 1-36 exerts antilipolytic effects
[28, 29]. We observed no effect of meal ingestion on circulating NPY 1-36 or NPY 3-36.
Previous studies measuring NPY using nonspecific immunoassays reported stable concen-
trations after meal ingestion [30] or a significant increase after ingestion after a meal with a
high glycemic index but not after ameal with a low glycemic index [31], but immunoassays do
not distinguish betweenNPY 1-36 and its metabolites. Interestingly, at 1 hour after themeal,
circulating NPY 1-36 correlated with norepinephrine concentrations regardless of crossover
treatment, consistent with colocalization of NPY 1-36 and norepinephrine in nerve terminals.
DPP4 inhibition with sitagliptin increased postprandial GLP-1 and decreased post-
prandial glucose in hypertensive patients with diabetes regardless of whether they were
taking an ACE inhibitor, an ARB, or a calcium channel blocker. As reported previously [26,
32], DPP4 inhibition decreased formation of the Y2 agonist PYY 3-36 without altering
postprandial PYY 1-36 concentrations, consistent with decreased PYY 1-36 secretion due to
feedback inhibition [33]. Because PYY 3-36 reduces food intake [34], decreased PYY 3-36may
contribute to the lack of effect of DPP4 inhibition on weight. In support of this, we found an
inverse relationship between PYY 3-36 and the desire to eat during placebo treatment but not
during either sitagliptin treatment.
We observed a substantial effect of sitagliptin on postprandial norepinephrine concen-
trations in hypertensive patients with diabetes taking either an ACE inhibitor or an ARB but
not in those taking amlodipine. We have previously reported an interactive effect of acute
ACE inhibition and DPP4 inhibition on norepinephrine concentrations [15]. Boschmann et al.
[25] reported higher norepinephrine concentrations in patients with diabetes, some of whom
were taking antihypertensive agents other than beta-blockers, but the authors did not report
what antihypertensive drugs the patients were taking. ACE and DPP4 share a common
substrate, substance P, which stimulates norepinephrine release [8, 16]. The finding that
cotreatment with the NK1/substance P receptor antagonist aprepitant abolished the increase
in norepinephrine suggests that substance P mediates stimulation of the sympathetic
nervous system. Importantly, aprepitant does not significantly affect gastric transit time
[35]. The finding that norepinephrine was increased by sitagliptin during valsartan as well as
during ramipril, however, indicates that the mechanism involves a pharmacodynamic in-
teraction between substance P and the RAAS rather than a pharmacokinetic effect of ACE
inhibition and DPP4 inhibition on substance P. Unfortunately, we were not able to measure
endogenous substance P using a specific assay in this study.
Increased norepinephrine concentrations during ramipril and valsartan were not related
to postprandial blood pressure. Norepinephrine was significantly higher at baseline (prior to
meal ingestion) during sitagliptin (vs placebo) in the ramipril group when baseline blood
pressure was not lower. In addition, postprandial norepinephrine was higher in both the
ramipril and valsartan treatment groups during sitagliptin, whereas postprandial blood
pressure was decreased only in the ramipril treatment arm. Despite the fact that concen-
trations of the vasoconstrictor NPY 1-36 were increased during sitagliptin and postprandial
norepinephrine concentrations were higher during sitagliptin in patients randomized to
either ramipril or valsartan, sitagliptin did not affect fasting blood pressure in any anti-
hypertensive treatment group, and postprandial blood pressure was decreased during
sitagliptin in patients taking the ACE inhibitor. This suggests the possibility that the va-
soconstrictor effects of norepinephrine and NPY 1-36 are offset by an endogenous vasodilator
in the postprandial period. In addition to stimulating the sympathetic nervous system,
substance P causes vasodilation; nevertheless, the observation that blocking the substance P
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(NK1) receptor tended to reduce blood pressure further during ramipril suggests that the
sympatho-stimulatory effects of endogenous substance P predominate. ACE inhibitors po-
tentiate bradykinin-mediated vasodilation, and bradykinin serves as a substrate for DPP4,
but only after it has been cleaved by aminopeptidase P [1, 36]. Increased GLP-1 during
sitagliptin may also have enhanced endothelium-dependent vasodilation during hyper-
insulinemia following themixedmeal [37]. The vasodilator brain natriuretic peptide (BNP) is
also a substrate of DPP4; however, BNP concentrations do not change in response to a meal
[38], and DPP4 inhibition with sitagliptin does not alter the vasodilator effect of BNP [39]. In
addition, the mechanisms for acute vs chronic blood pressure changes may be different.
Jackson et al. [40] and others [41] have shown that, during acute DPP4 inhibition in animal
models and ex vivo, changes in blood pressure are mediated by DPP4 substrates on the
vasculature to affect peripheral vascular resistance. During chronic DPP4 inhibition with
sitagliptin, however, DPP4 substrate activity at the level of the kidney and renovasular
responsiveness/tone may contribute to increases in blood pressure seen in hypertensive
animals during DPP4 inhibition compared with baseline and vs normotensive animals [40].
Similarly, in humans, acute vs chronic changes in NPY and renovascular tone may
also contribute.
Regardless of the effects on blood pressure, increased NPY 1-36 and substance P–
dependent increases in norepinephrine during inhibition of the RAAS could contribute to a
lack of cardiovascular benefit of treatment with DPP4 inhibitors compared with GLP-1
agonists [42] as well as to increased risk of heart failure in some clinical trials of DPP4
inhibitors. Immunoreactive NPY and norepinephrine are increased during heart failure
exacerbations and are associated with poor outcomes in patients with heart failure [19, 43,
44]. Although large cardiovascular outcomes studies of DPP4 inhibitors did not report
neuropeptide or norepinephrine concentrations, it is possible that these may have been
higher during DPP4 inhibition with saxagliptin (SAVOR-TIMI 53) and those without prior
history of heart failure during alogliptin (EXAMINE) to contribute to the heart failure signal
in these subjects [5, 6]. However,.70% of patients took an ACE inhibitor or ARB during the
cardiovascular outcomes trials, thus limiting potential comparison of RAAS therapies to
alternative antihypertensive therapies (such as calcium channel blockade, as we were able to
in the current study), and there may have been confounding due to concurrent medication
use, such as beta blockade [4, 6, 45].
In summary, DPP4 inhibition shifts the relationship between Y1 agonists and Y2 agonists
after a meal. DPP4 inhibition increased NPY 1-36 concentrations through a substance P
receptor–independent mechanism, specifically through decreased degradation. In contrast,
during inhibition of the RAAS by either an ACE inhibitor or an ARB, DPP4 inhibition in-
creased postprandial norepinephrine through a substance P–dependent mechanism. Future
studies are needed to determine the long-term consequences of increases in Y1 agonists
and norepinephrine.
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